Division of Medical Oncology, Department of Oncology, Queen's University, Kingston, ON, Canada.
Department of Urology, Queen's University, Kingston, ON, Canada.
Eur Urol. 2021 Aug;80(2):123-126. doi: 10.1016/j.eururo.2021.03.001. Epub 2021 Mar 26.
For patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after an androgen receptor axis-targeted therapy and docetaxel, poly (ADP-ribose) polymerase (PARP) inhibitors and chemotherapy with cabazitaxel have shown promise. We address the trials for the two approaches and consider possible sequencing of these drugs. We suggest that only patients with a BRCA2 mutation should receive a PARP inhibitor, and docetaxel or cabazitaxel should be favored in the absence of BRCA2 alterations, provided the patient is naïve to these drugs.
对于雄激素受体轴靶向治疗和多西他赛后进展的转移性去势抵抗性前列腺癌（mCRPC）患者，聚（ADP-核糖）聚合酶（PARP）抑制剂和卡巴他赛化疗显示出前景。我们讨论了这两种方法的临床试验，并考虑了这些药物的可能顺序。我们建议只有 BRCA2 突变的患者才应接受 PARP 抑制剂，并且在没有 BRCA2 改变的情况下，应优先考虑多西他赛或卡巴他赛，前提是患者对这些药物没有耐药性。
